Our Company Strategy & Mission Leadership Our Board Partnering Opportunities Out-Licensing Opportunities Contact Our Pipeline Clinical Trials Clinical Trials Compassionate Use Disease Information Innovation Engine Akeso Partnership Overview Ivonescimab (SMT112) Overview Therapeutic Areas News Center Media Resources Press Releases Investor Center Investor Center Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Board of Directors Diversity Matrix Shareholder Meetings Summit Presentations Career Opportunities
The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridioides difficile Antibiotic The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridioides difficile Antibiotic April 25, 2023 By Dave Gancarz
The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridioides difficile Antibiotic April 25, 2023 By Dave Gancarz
Website Cookies This website uses cookies: Please see our Privacy Policy to understand how we use cookies. Okay, thanks
